Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384341 | 0.82 | MAOB (0.78) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL29369517 | 0.82 | MAOB (0.78) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2785214 | 0.81 | MAOB (0.71) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12921043 | 0.81 | TDP1 (0.56) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL34466860 | 0.81 | TDP1 (0.56) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL11739144 | 0.81 | MAOB (0.59) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL24379235 | 0.80 | SMPD1 (0.49) | MAOBMAPTSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL5801964 | 0.80 | MAOB (0.69) | MAOBMAOAMEN1KMT2A | |
| SCHEMBL7282913 | 0.79 | MAOB (0.68) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10750881 | 0.77 | MAOB (0.74) | MAOBMAPTCYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | MAOB 1288/4885MAPT 3668/4885CYP2C9 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.